Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The development marks a significant step in integrating artificial intelligence into pharmaceutical production, with implications for efficiency, compliance, and scalability across the industry.
The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. By combining PDAOAI with TechForce’s autonomous robotic systems, the integrated platform supports intelligent pharmaceutical manufacturing and creates potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services (CDMO).
The announcement is important because it demonstrates a concrete application of AI in regulated pharmaceutical manufacturing, an area where automation can reduce human error, improve batch consistency, and lower costs. The platform’s ability to handle electronic batch records and GMP workflows directly addresses regulatory compliance challenges, while autonomous materials movement and cleanroom monitoring enhance operational safety and efficiency. For Oncotelic, this initiative diversifies its business model beyond drug development, potentially generating revenue through software licensing and CDMO services.
Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector. The company’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents, underscoring the intellectual property foundation underlying these technologies.
As a clinical-stage biopharmaceutical company, Oncotelic focuses on oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company also owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates. The PDAOAI platform supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration, further strengthening Oncotelic’s position in oncology and rare disease therapeutics.
For more information, see the full press release at https://nnw.fm/j1n43. Latest news and updates are available at https://nnw.fm/OTLC.
